KTTAW vs REGN
Pasithea Therapeutics Corp. Warrant (KTTAW) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Pasithea Therapeutics Corp. Warrant (KTTAW) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
KTTAW does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
KTTAW currently screens at market cap $0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the KTTAW and REGN stock pages for the full models.
Not investment advice.